Alithea Genomics
Lausanne, CH · 2 known investors
Alithea Genomics develops extraction-free, high-throughput RNA sequencing kits and workflows, including massively multiplexed bulk RNA-seq and plate-based single-cell RNA-seq, that skip RNA isolation and support up to 384 or 1536-well library preparation. Its products serve pre-clinical drug discovery and chemical safety teams for applications such as compound screening, mechanism-of-action mapping, and toxicity profiling.
BiotechDeep TechHealthtech
Investors · 2
Frequently asked questions
- What does Alithea Genomics do?
- Alithea Genomics develops extraction-free, high-throughput RNA sequencing kits and workflows, including massively multiplexed bulk RNA-seq and plate-based single-cell RNA-seq, that skip RNA isolation and support up to 384 or 1536-well library preparation. Its products serve pre-clinical drug discovery and chemical safety teams for applications such as compound screening, mechanism-of-action mapping, and toxicity profiling.
- Who are Alithea Genomics's investors?
- Alithea Genomics's investors include Kickfund, Novalis Biotech.
- Where is Alithea Genomics headquartered?
- Alithea Genomics is headquartered in Lausanne, CH.